R&D

 Projects 1: stem cell-based immunotherapy The “stem cell-based immunotherapy” is an international multicentral project between the P7Medicine R&D group, the Institute for Neurophysiology at the University of Cologne, and the Cancer Institute at the Tehran University of Medical Sciences (TUSM). The main target of this project is to develop and evaluate individualized adaptive immune cells from the stem cells (IPSCs and fetal stem cells) for cancer immunotherapy. This project was established in 2018 at the Tehran University of Medical Sciences (RCT code: IRCT20200429047241N1). This project’s last findings were published in the “Cancer Immunology, Immunotherapy” journal entitled “Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in the treatment of advanced solid tumors.” You can access the article on this page. Our article’s artwork is on the cover of “the “Cancer Immunology, Immunotherapy” journal. This figure presents the development of the immune cells from hematopoietic cells.

2: Origin of Tumor Cell Development (OTCD) The mechanisms of malignant tumor cells’ creation and development are still a central question in front of scientists. In the OTCD, we are trying to answer this central query using advanced cellular and molecular technology by inspiring the developmental biology view. We believe the OTCD findings will be able to make a fundamental evolution in the cancer personalized medicine. This project is supported by the P7Medicine R&D team, Cancer Institute of Tehran University of Medical Sciences (TUSM), and Breast Diseases Research Center of Tehran University of Medical Sciences (TUSM). The OTCD consists of two individual studies registered in the Tehran University of Medical Sciences (TUSM) by registration codes 99-1-115-47842 and 1400-3-259-54530. Publicities As the last epidemiological observation announced, cardiovascular disease (CVD) and cancer are the leading causes of human death worldwide. Hence, developing new effective, personalized strategies for early detection and treatment of these disorders manages to save many lives every year. Besides the cancer, our team’s effort is to develop a new regenerative approach using stem cell technology for CVD. We are standing on the idea that autologous stem cell technology can be a safe and effitent personalized method to achieve this target. The P7Medicine researchers, under Prof. Nayernia’s supervision, in collaboration with many research institutes, including the Institute for Neurophysiology at the University of Cologne in Germany, Cologne Center for Immunoncology (IOZK) in Germany, and Tehran University of Medical Sciences (TUSM) in Iran has done many investigations in this fields. The below publications are some of our R&D group. You can access the article on this page. – Mardanpour, Parisa, Karim Nayernia, Saeed Khodayari, Hamid Khodayari, Marek Molcanyi, and Jürgen Hescheler. “Application of stem cell technologies to regenerate injured myocardium and improve cardiac function.” Cell Physiol Biochem 53, no. 1 (2019): 101-120. – Khodayari, Saeed, Hamid Khodayari, Ali Zahedi Amiri, Maryam Eslami, Dariush Farhud, Jürgen Hescheler, and Karim Nayernia. “Inflammatory microenvironment of acute myocardial infarction prevents regeneration of heart with stem cells therapy.” Cell Physiol Biochem 53, no. 5 (2019): 887-909. – Khodayari, Saeed, Hamid Khodayari, Somayeh Ebrahimi-Barough, Mehdi Khanmohammadi, Md Shahidul Islam, Miko Vesovic, Arash Goodarzi et al. “Stem Cell Therapy in Limb Ischemia: State-of-Art, Perspective, and Possible Impacts of Endometrial-Derived Stem Cells.” Frontiers in cell and developmental biology 10 (2022).